REGENX BIOSCIENCES, LLC

Basic Information

750 17TH ST NW, STE 1100
WASHINGTON, DC, 20006-

Company Profile

n/a

Additional Details

Field Value
DUNS: 829689608
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

    Amount: $261,327.00

    DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related m ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. AAV Mediated Gene Transfer to the CNS for MPS I

    Amount: $211,009.00

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis type I (MPS I) is an autosomal recessive storage disease caused by the absence of a-L-iduronidase (IDUA), resulting in systemic accumulation ...

    STTR Phase I 2012 Department of Health and Human Services
  3. Novel Adeno-Associated Viral Therapy for Wet Age-Related Macular Degeneration

    Amount: $304,421.00

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel gene-based delivery system to treat neovascular age- related macular degeneration (wet AMD), a debilitating ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Scalable Production of New Generation Adeno-Associated Virus Gene Therapy Vectors

    Amount: $263,277.00

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop a scalable production system for the manufacture of an adeno- associated virus (AAV) serotype 8-based gene thera ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government